RxDoctor Payments Data

Kerry Reynolds, PA

Physician Assistant · Ogden, UTNPI 1306034616

Payments from drug & device makers

$4,323in general payments, 2019–2025

Across 287 payments — averaging $15.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$993
  • Lilly USA, LLC$447
  • AstraZeneca$331
  • GSK$285
  • Pfizer$270
  • Astellas Pharma US Inc$197
  • plus $2K from 37 others

What the payments were for

  • Food & beverage$4,323100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,323 in reported general payments places this provider in the 90th percentile of 1,543 physician assistant providers in Utah.

See all physician assistant providers in Utah

Medicare billing

Part B allowed, 2024
$40,347
Medicare patients
177
Services billed
1,373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol57$47,645
JardianceEmpagliflozin37$32,228
XareltoRivaroxaban27$29,714
OzempicSemaglutide20$27,605
TrulicityDulaglutide22$21,559
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$18,473
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$14,782
MyrbetriqMirabegron18$13,521
RybelsusSemaglutide13$12,576
GlyxambiEmpagliflozin/Linagliptin14$11,813
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$8,572
EntrestoSacubitril/Valsartan12$8,284
Lantus SolostarInsulin Glargine,hum.Rec.Anlog37$4,717
Incruse ElliptaUmeclidinium Bromide11$3,923
Novolog FlexpenInsulin Aspart15$3,247

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere$331$66,11779 claims
Boehringer IngelheimJardiance, Glyxambi$93$44,04151 claims
Novo NordiskOzempic, Rybelsus$37$40,18133 claims
Johnson & JohnsonXarelto$71$29,71427 claims
Lilly USA, LLCTrulicity$447$21,55922 claims
Astellas Pharma US IncMyrbetriq$197$13,52118 claims
GSKIncruse Ellipta$285$3,92311 claims
AbbVieSynthroid$993$77115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,543 physician assistant providers in Utah.

Other physician assistant in Ogden

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →